Ms. Jin-Hua Zhang is the Founder, Chairwoman, and CEO of IASO Bio. She graduated from Dongbei University of Finance and Economics with a Master’s degree in Law and is a seasoned securities lawyer. Her career includes significant roles in investment banking and leading securities law firms. As a project leader, she has successfully dual-hatted as both financial advisor and lawyer, overseeing numerous IPOs and M&A projects for Chinese companies. Her expertise spans domestic A-share restructurings, and listings on the Hong Kong Stock Exchange, NASDAQ in the U.S., and the Toronto Stock Exchange in Canada. Since 2003, Ms. Zhang has led nearly 20 M&A projects for publicly listed companies and has facilitated the listings of dozens of companies both domestically and internationally. In 2015, she made an angel investment in an early-stage company focused on CAR-T research and served as a board member.
In 2017, Ms. Zhang founded IASO Bio with the mission of "focusing on innovative biological therapies to bring hope of a cure to patients," dedicated to addressing the unmet clinical needs of patients in China and worldwide. Since its inception, she has led and managed a core team of experts from biotechnology, medicine, antibody development, and pharmaceutical sales fields, all working together on the research, clinical development, production, and commercialization of cell therapy technologies.
Ms. Zhang is also an Executive Director of the Jiangsu Federation of Enterprises and the Jiangsu Entrepreneur Association.
Dr. Yongke Zhang serves as the Chief Scientific Officer at IASO Bio, bringing with him a distinguished track record and profound academic foundation in biopharmaceutical research and development. With over 20 years of R&D experience in biopharmaceuticals and nearly a decade of expertise in oncology and autoimmune disease diagnosis, treatment, and clinical research, Dr. Zhang is a seasoned leader in the field.
Prior to joining IASO Bio, Dr. Zhang gained extensive experience in the U.S. biopharmaceutical industry. He was the co-founder and Chief Scientist of Abcyte Therapeutics, where he spearheaded multiple antibody and multifunctional CAR-T projects, including the development of Narsoplimab injection for the Chinese market. Additionally, he co-founded and served as Senior Director of R&D at Apenexigen, where he led the development of the CD40 agonist immunomodulatory antibody (sotigalimab) aimed at treating advanced pancreatic cancer.
Earlier in his career, Dr. Zhang was the Director of Therapeutic Rabbit Monoclonal Antibody Development at Epitomics, where he oversaw the development of several antibody drugs, including the successful market introduction of the rabbit-derived antibody Brolucizumab. During his tenure at PDL Biopharma (now AbbVie), he worked as a Senior Scientist and Group Leader, contributing to the development of several antibody drugs, most notably Elotuzumab, which successfully reached the market.
Dr. Zhang earned a joint M.D. degree in Clinical Medicine from Peking Medical University and Chiba University in Japan, a Ph.D. in Molecular and Cellular Biology from the University of Tokyo, and completed his postdoctoral research at the DNAX Research Institute (now Merck Research Laboratories) in the United States.
Mr. Hua Zhang serves as the Chief Commercial Officer at IASO Bio. He is a leader with profound insight and significant influence in pharmaceutical marketing, bringing over 20 years of experience in managing marketing and sales departments within the pharmaceutical industry. Mr. Zhang has accumulated extensive practical experience, particularly in the launch and promotion of innovative oncology drugs. Prior to joining IASO Bio, he was the Deputy Chief Commercial Officer at Fosun Kite Biotechnology, where he led the team to successfully launch Yescarta, the first CAR-T therapy approved in China. Before that, he held several key positions, including Specialty Medicine Sales Director at Bayer Pharmaceuticals, North China Marketing Director at Merck Serono, and Sales Director for Pfizer Oncology, where he spearheaded market promotion and commercial operations for the companies' products.
Mr. Zhang holds a Bachelor's degree in Pharmacology from Shanghai Medical College and an MBA from Fudan University.
Dr. Fu is the Chief Financial Officer at IASO Bio, distinguished for his exceptional leadership at the intersection of scientific research and finance. He brings over 20 years of extensive experience in capital markets, financial management, and scientific research. Before joining IASO Bio, Dr. Fu served as Managing Director at Haitong International and Director at Citigroup Global Markets, where he led and facilitated the successful listings of numerous Chinese companies in Hong Kong and the United States, including several in the healthcare sector. Previously, he worked at Davis Polk & Wardwell in Hong Kong and Skadden, Arps, Slate, Meagher & Flom in Palo Alto, focusing on capital market transactions such as IPOs and bond issuances. Earlier in his career, he was a research scientist at Rigel Pharmaceuticals, specializing in immunology and oncology research and drug development.
Dr. Fu holds a Juris Doctor (J.D.) degree from the University of California, Berkeley, a Ph.D. in Molecular Genetics from Washington University in St. Louis, a Master's degree in Immunology from the Shanghai Institute of Cell Biology, Chinese Academy of Sciences, and a Bachelor's degree in Genetics and Genetic Engineering from Fudan University.